Tear Osmolarity Changes After Instilling Isotonic Hyaluronate Artificial Tears
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01614847 |
Recruitment Status
:
Completed
First Posted
: June 8, 2012
Last Update Posted
: June 20, 2013
|
Tracking Information | |||
---|---|---|---|
First Submitted Date ICMJE | June 6, 2012 | ||
First Posted Date ICMJE | June 8, 2012 | ||
Last Update Posted Date | June 20, 2013 | ||
Study Start Date ICMJE | June 2012 | ||
Actual Primary Completion Date | August 2012 (Final data collection date for primary outcome measure) | ||
Current Primary Outcome Measures ICMJE |
Osmolarity (mOsms/L) as a function of time (minutes) [ Time Frame: Approximately 1 hours post instillation ] Following instillation of artificial tears, we will collect a 50-nl sample of tears using the TearLab device, which will report osmolarity of the tear film. We will measure every 15 minutes following instillation, for up to 2 hours.
|
||
Original Primary Outcome Measures ICMJE | Same as current | ||
Change History | Complete list of historical versions of study NCT01614847 on ClinicalTrials.gov Archive Site | ||
Current Secondary Outcome Measures ICMJE | Not Provided | ||
Original Secondary Outcome Measures ICMJE | Not Provided | ||
Current Other Outcome Measures ICMJE | Not Provided | ||
Original Other Outcome Measures ICMJE | Not Provided | ||
Descriptive Information | |||
Brief Title ICMJE | Tear Osmolarity Changes After Instilling Isotonic Hyaluronate Artificial Tears | ||
Official Title ICMJE | Tear Osmolarity Changes After Instilling Isotonic Hyaluronate Artificial Tears | ||
Brief Summary | Background: Osmolarity is defined as the concentration of particles dissolved in a solution. Normal tears contain various dissolved particles including proteins, salts and other electrolytes. The investigators plan to investigate how osmolarity of the tear film changes over time after instillation of artificial tears containing hyaluronate. This is one kind of artificial tear that is used to treat dry eye. Dry eye and tear osmolarity: Dry eye is a significant health problem, but diagnosis and treatment are often ambiguous and ineffective. There has been a resurgence of interest and research in dry eye in the past 5 years, and tear osmolarity has emerged as perhaps, one of the most effective ways to evaluate tear quality and dry eye status. Dry eye is usually treated with artificial tears, and many formulations are available. The investigators will test an isotonic solution that contains hyaluronate. Hyaluronate binds water and should help to maintain water on the eye. Objective: We plan to study the time course of possible changes in tear film osmolarity following instillation of an isotonic artificial tear containing hyaluronate. The investigators will use the TearLab, a new clinical instrument that has been developed to quickly and easily measure tear film osmolarity. Understanding how artificial tears affect tear film osmolarity over time can help doctors determine efficacy and dosing schedules. The investigators will test the isotonic hyaluronate (Blink Contacts) artificial tears relative to normal saline solution. Hypothesis: The investigators should be able to measure a decrease in tear osmolarity over time following instillation due to the water-binding effect of hyaluronate artificial tears relative to a control (normal saline solution). |
||
Detailed Description | ABSTRACT: Introduction: Tear hyper-osmolarity may be a fundamental cause of dry eye in many cases. Hyaluronate is an agent used in some artificial tears, which binds water and can protect against evaporation. It may therefore be an effective treatment for tear hyper-osmolarity. Purpose: Our purpose was to measure changes in tear osmolarity over time following instillation of Blink Contacts, an isotonic ocular lubricant containing hyaluronate. We hypothesized that even in isotonic solution, the water-binding properties of hyaluronate would reduce tear osmolarity. This will help us better understand efficacy of this treatment and develop a rational basis for dosing schedules. Methods: After baseline osmolarity measurements, eight subjects received either Blink Contacts or normal saline drops in both eyes. We re-measured osmolarity five minutes later, and then at 15-minute intervals up to 95 minutes. Subjects also rated comfort at each time. The next day, the experiment was repeated with the alternate drops for each subject. Results: There was no statistically or clinically significant decrease in tear osmolarity over time for either Blink Contacts or normal saline, and there was no significant difference between the drops. Comfort ratings showed no significant difference at any time. Conclusions: We conclude, although hyaluronate binds water, it does not significantly alter tear osmolarity when its osmolarity is similar to that of the tears. However, it may reduce osmolarity when it is more hypotonic relative to the tears. Small sample size, few eyes with hyperosmolarity and limitations of our methods may have affected results. |
||
Study Type ICMJE | Interventional | ||
Study Phase | Not Applicable | ||
Study Design ICMJE | Allocation: Randomized Intervention Model: Crossover Assignment Masking: Double (Participant, Investigator) Primary Purpose: Treatment |
||
Condition ICMJE | Dry Eye | ||
Intervention ICMJE | Drug: Artificial tears
At random, subjects will receive hypo-osmolar artificial tear or a control (normal saline). |
||
Study Arms |
|
||
Publications * | Not Provided | ||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||
Recruitment Information | |||
Recruitment Status ICMJE | Completed | ||
Actual Enrollment ICMJE |
8 | ||
Original Estimated Enrollment ICMJE |
12 | ||
Actual Study Completion Date | August 2012 | ||
Actual Primary Completion Date | August 2012 (Final data collection date for primary outcome measure) | ||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||
Sex/Gender |
|
||
Ages | 18 Years and older (Adult, Senior) | ||
Accepts Healthy Volunteers | Yes | ||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||
Listed Location Countries ICMJE | United States | ||
Removed Location Countries | |||
Administrative Information | |||
NCT Number ICMJE | NCT01614847 | ||
Other Study ID Numbers ICMJE | NSUOCO-2012-11 | ||
Has Data Monitoring Committee | No | ||
U.S. FDA-regulated Product | Not Provided | ||
IPD Sharing Statement | Not Provided | ||
Responsible Party | Thomas O Salmon, OD, PhD, Northeastern State University | ||
Study Sponsor ICMJE | Thomas O Salmon, OD, PhD | ||
Collaborators ICMJE | Not Provided | ||
Investigators ICMJE | Not Provided | ||
PRS Account | Northeastern State University | ||
Verification Date | June 2013 | ||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |